West Pharmaceutical Servs Q3 2024 Adj. EPS $1.85 Beats $1.50 Estimate, Sales $746.900M Beat $709.616M Estimate
Portfolio Pulse from Benzinga Newsdesk
West Pharmaceutical Services reported Q3 2024 adjusted EPS of $1.85, surpassing the estimated $1.50. The company's sales reached $746.9 million, exceeding the forecasted $709.616 million.
October 24, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
West Pharmaceutical Services reported better-than-expected Q3 2024 results with an adjusted EPS of $1.85 and sales of $746.9 million, both exceeding analyst estimates.
The company's Q3 2024 earnings and sales both exceeded analyst expectations, which is likely to positively impact the stock price in the short term as it indicates strong financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100